Owlstone Medical, a SBRI Healthcare backed diagnostics company, has announced that their innovative disease breathalyser will feature in the Tomorrow’s World gallery at the Science Museum, London.
The exhibition aims to inspire visitors with award-winning, cutting-edge scientific advances such as advanced surgical robotics, space suits and avalanche analysis technology. Owlstone’s disease breathalyser, ReCIVA™, was selected to feature based on its potential to revolutionise healthcare and bring real benefits to patients, and will be on display from 18 August.
Owlstone Medical’s CE-marked ReCIVA Breath Sampler forms part of the Company’s Breath Biopsy® platform, which analyses biomarkers from breath to diagnose disease. ReCIVA is used to collect samples of breath from a patient, completely non-invasively, and analyse them with high sensitivity and selectivity.
Each exhaled breath contains a rich spectrum of Volatile Organic Compounds (VOCs) produced by the body’s metabolism that relate directly to disease activity. When analysed, this information can enable early diagnosis and provide important insights for patient stratification, helping to ensure that the right therapy is given to the right patient at the right time, to improve clinical outcomes and reduce healthcare costs.
Billy Boyle, co-founder and CEO at Owlstone Medical commented:
“Our Breath Biopsy platform presents a new approach to detect disease earlier and make better treatment decisions for patients. The ReCIVA Breath Sampler is a reliable and reproducible way to capture VOC biomarkers in breath samples, which can be sent to Owlstone Medical’s clinical laboratory in Cambridge for analysis. The technology is already in use in over 60 research and clinical labs globally, and we are honored that it has been selected to feature in the Science Museum’s Tomorrow’s World gallery.”
To find out more about Owlstone Medical visit: www.owlstonemedical.com
The Science Museum is part of the Science Museum Group, open seven days a week, 10.00 – 18.00